Olaratumab Alternatives Compared
Olaratumab | Votrient | Pazopanib |
|
---|
Olaratumab | Votrient (pazopanib) | Pazopanib |
|
|||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Prescription only
Prescribed for Soft Tissue Sarcoma. olaratumab may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Soft Tissue Sarcoma, Renal Cell Carcinoma. Votrient may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Soft Tissue Sarcoma, Renal Cell Carcinoma. pazopanib may also be used for purposes not listed in this medication guide. |
Related suggestions Soft Tissue Sarcoma
|
|||||||||||||||
More about Olaratumab | More about Votrient (pazopanib) | More about Pazopanib | ||||||||||||||||
Ratings & Reviews | ||||||||||||||||||
Be the first to share your experience with this drug. |
Votrient has an average rating of 8.2 out of 10 from a total of 82 ratings on Drugs.com. 77% of reviewers reported a positive effect, while 7% reported a negative effect. |
Pazopanib has an average rating of 8.2 out of 10 from a total of 91 ratings on Drugs.com. 76% of reviewers reported a positive effect, while 8% reported a negative effect. |
||||||||||||||||
Drug Class | ||||||||||||||||||
Side Effects | ||||||||||||||||||
See also: olaratumab side effects in more detail. |
See also: Votrient side effects in more detail. |
See also: pazopanib side effects in more detail. |
||||||||||||||||
Generic Availability | ||||||||||||||||||
N/A |
Lower cost generic |
|||||||||||||||||
Pricing and Coupons * Prices are without insurance | ||||||||||||||||||
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Votrient prices |
View all pazopanib prices |
||||||||||||||||
Dosage Form(s) Available | ||||||||||||||||||
N/A |
|
|
||||||||||||||||
Brand Names | ||||||||||||||||||
N/A |
N/A |
Votrient | ||||||||||||||||
Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||||||||||
576 hours |
30.9 hours |
30.9 hours |
||||||||||||||||
CSA Schedule ** View glossary of terms | ||||||||||||||||||
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
Pregnancy Category | ||||||||||||||||||
Summary unavailable. See the full pregnancy warnings document. |
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
||||||||||||||||
Drug Interactions | ||||||||||||||||||
A total of 149 drugs are known to interact with olaratumab:
|
A total of 662 drugs are known to interact with Votrient:
|
A total of 662 drugs are known to interact with pazopanib:
|
||||||||||||||||
Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
|
||||||||||||||||
Disease Interactions | ||||||||||||||||||
First Approval Date | ||||||||||||||||||
N/A |
October 19, 2009 |
October 19, 2009 |
||||||||||||||||
WADA Class View World Anti-Doping Agency classifications. | ||||||||||||||||||
N/A |
N/A |
N/A |
||||||||||||||||
More Information | ||||||||||||||||||
Patient resources | ||||||||||||||||||
Professional Resources | ||||||||||||||||||
Related Treatment Guide | ||||||||||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.